Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Managing diffuse large B-cell lymphoma

Christian Gisselbrecht • 5 Dec 2014
ASH 2014
B-Cell Lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses the molecular approach in managing diffuse large B-cell lymphoma (DLBCL). The molecularly defined DLBCL subtypes, germinal centre B-cell-like (GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL, have important clinical implications.

More from Christian Gisselbrecht

Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
The current status of autologous transplantation in PTCL
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals